Blood expression levels of chemokine receptor CCR3 and chemokine CCL11 in age-related macular degeneration: a case–control study

BMC Ophthalmology

Research Article

Mads Krüger Falk¹  Amardeep Singh¹  Torben Lykke Sørensen¹  Thomas Hviid²  Carsten Faber³  Mogens Holst Nissen³ 

[1] Clinical Eye Research Unit, Department of Ophthalmology, Copenhagen University Hospital Roskilde, Denmark and Faculty of Health Sciences, University of Copenhagen, Køgevej 7-13, DK-4000, Roskilde, Denmark;Department of Clinical Biochemistry, Center for Immune Regulation and Reproductive Immunology, Copenhagen University Hospital Roskilde, Denmark and Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark;Department of Microbiology, Immunology & International Health, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark;

关键词: Age-related macular degeneration;    chemokine;    CCR3;    CCL11;   

DOI  :  10.1186/1471-2415-14-22

 received in 2013-12-23, accepted in 2014-02-19,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundDysregulation of the CCR3/CCL11 pathway has been implicated in the pathogenesis of choroidal neovascularisation, a common feature of late age-related macular degeneration (AMD). The aim of this study was to investigate the expression of CCR3 and its ligand CCL11 in peripheral blood in patients with neovascular AMD.MethodsPatients with neovascular AMD and healthy controls were included. Blood samples were obtained and prepared for flow cytometry to investigate the expression of CCR3. Levels of CCL11 were measured in plasma using Cytometric Bead Array. Differences between the groups were tested using Kruskal-Wallis test and Mann–Whitney U test.ResultsPatients (n = 83) with neovascular AMD and healthy control persons (n = 114) were included in the study. No significant difference in the expression of CCR3 was found on CD9+ granulocytes when comparing patients suffering from neovascular AMD with any of the control groups. We did not find any alteration in CCL11 levels in patients among the age matched groups. There was no correlation between expression of CCR3/CCL11 and clinical response to treatment with anti-vascular endothelial growth factor (VEGF).ConclusionOur results do not suggest a systemic alteration of the CCR3/CCL11 receptor/ligand complex in patients with neovascular AMD.

【 授权许可】

CC BY   
© Falk et al.; licensee BioMed Central Ltd. 2014